Sturrock, M, Miller, IS, Kang, G et al. (7 more authors) (2018) Anti-angiogenic drug scheduling optimisation with application to colorectal cancer. Scientific Reports, 8 (1). 11182. ISSN 2045-2322
Abstract
Bevacizumab (bvz) is a first choice anti-angiogenic drug in oncology and is primarily administered in combination with chemotherapy. It has been hypothesized that anti-angiogenic drugs enhance efficacy of cytotoxic drugs by “normalizing” abnormal tumor vessels and improving drug penetration. Nevertheless, the clinical relevance of this phenomenon is still unclear with several studies over recent years suggesting an opposing relationship. Herein, we sought to develop a new computational tool to interrogate anti-angiogenic drug scheduling with particular application in the setting of colorectal cancer (CRC). Specifically, we have employed a mathematical model of vascular tumour growth which interrogates the impact of anti-angiogenic treatment and chemotherapeutic treatment on tumour volume. Model predictions were validated using CRC xenografts which underwent treatment with a clinically relevant combinatorial anti-angiogenic regimen. Bayesian model selection revealed the most appropriate term for capturing the effect of treatments on the tumour size, and provided insights into a switch-like dependence of FOLFOX delivery on the tumour vasculature. Our experimental data and mathematical model suggest that delivering chemotherapy prior to bvz may be optimal in the colorectal cancer setting.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © The Author(s) 2018. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Molecular Gastroenterology (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 13 Dec 2018 12:41 |
Last Modified: | 13 Dec 2018 12:41 |
Status: | Published |
Publisher: | Nature Research |
Identification Number: | 10.1038/s41598-018-29318-5 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:139956 |
Commentary/Response Threads
-
Sturrock, M, Miller, IS, Kang, G, Hannis Arba’ie, N, O’Farrell, AC, Barat, A, Marston, G, Coletta, PL, Byrne, AT and Prehn, JH
Anti-angiogenic drug scheduling optimisation with application to colorectal cancer. (deposited 13 Dec 2018 12:41)
[Currently Displayed]
- Sturrock, M, Miller, IS, Kang, G, Hannis Arba'ie, N, O'Farrell, AC, Barat, A, Marston, G, Coletta, PL, Byrne, AT and Prehn, JH Author Correction: Anti-angiogenic drug scheduling optimisation with application to colorectal cancer. (deposited 23 Jan 2019 13:51)
Download
Filename: Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.pdf
Licence: CC-BY 4.0